{"result": "(\"entity\"<|>XENICAL<|>ORGANIZATION<|>Xenical is a weight loss medication that is compared with cetilistat in clinical trials for obesity treatment.)\n##\n(\"entity\"<|>CETILISTAT<|>ORGANIZATION<|>Cetilistat is a weight loss medication evaluated in a randomized, placebo-controlled trial for its efficacy in obese diabetics.)\n##\n(\"entity\"<|>TESOFENSINE<|>ORGANIZATION<|>Tesofensine is a drug studied for its effects on body weight loss and quality of life in obese patients.)\n##\n(\"entity\"<|>BELORANIB<|>ORGANIZATION<|>Beloranib is a medication assessed for its efficacy and safety in weight loss among obese adults.)\n##\n(\"entity\"<|>PYY3-36<|>ORGANIZATION<|>PYY3-36 is a hormone studied for its effects on energy intake and appetite in overweight individuals.)\n##\n(\"entity\"<|>GLP-1<|>ORGANIZATION<|>GLP-1 is a hormone involved in the regulation of appetite and energy expenditure, studied in relation to obesity treatment.)\n##\n(\"entity\"<|>NAT MED<|>ORGANIZATION<|>Nature Medicine is a journal that published research on a rationally designed peptide for obesity and diabetes treatment.)\n##\n(\"relationship\"<|>CETILISTAT<|>XENICAL<|>Cetilistat is compared with Xenical in clinical trials for weight loss efficacy.<|>7)\n##\n(\"relationship\"<|>TESOFENSINE<|>OBESITY<|>Tesofensine is studied for its effects on weight loss in obese patients.<|>8)\n##\n(\"relationship\"<|>BELORANIB<|>OBESITY<|>Beloranib is evaluated for its effectiveness in promoting weight loss in obese adults.<|>8)\n##\n(\"relationship\"<|>PYY3-36<|>GLP-1<|>PYY3-36 and GLP-1 are both hormones studied for their roles in appetite regulation and energy expenditure in obesity treatment.<|>6)\n##\n(\"relationship\"<|>NAT MED<|>TESOFENSINE<|>Nature Medicine published research on the effects of tesofensine on obesity and diabetes.<|>7)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: s 1-Year Weight Loss and is Associated with Improvements in Clinical Markers. Obesity (Silver Spring). 2016; 24:2278-2288.\n\n32. Kopelman P, Groot GH, Rissanen A, Rossner S, Toubro S, Palmer R, Hallam R, Bryson A, Hickling RI. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled\n---\nTema 8. Tratamiento farmacológico de la obesidad    141\n\nphase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity. 2010; 18:108-15.\n\n33. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 378: 1906-13.\n\n34. Kim DD, Krishnarajah J, Lillioja S, de Looze F, Marjason J, Proietto J, et al. Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial.Diabetes Obes Metab. 2015; 17:566-72.\n\n35. Irwin N, Flatt PR. Enteroendocrine hormone mimetics for the treatment of obesity and diabetes. Curr Opin Pharmacol. 2013; 13:989-95.\n\n36. Bhat VK, Kerr BD, Flatt PR, Gault VA.A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties. Biochem Pharmacol. 2013; 85:1655-62.\n\n37. Schmidt JB, Gregersen NT, Pedersen SD, Arentoft JL, Ritz C, Schwartz TW, et al. Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men. Am J Physiol Endocrinol Metab. 2014; 306:E1248-56.\n\n38. Finan B, Yang B, Ottaway N, Smiley DL, Ma T, Clemmensen C, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015; 21:27-36.\n---\nThe image appears to be a blank white page. There is no visible content, text, diagrams, or any other information present in this image. Therefore, I cannot provide any markdown translation or description of content, as there is nothing to transcribe or describe.\n---\n# Tema 9.\n## Obesidad: Tratamiento quirúrgico\n\nIrene Bretón\nCynthia González-Antigüedad\nMarta Motilla\nAna Zugasti\nPilar García-Peris\nUnidad de Nutrición Clínica y Dietética. Servicio de Endocrinología y Nutrición. Hospital General\nUniversitario Gregorio Marañón. Madrid\n\nDietoterapia, nutrición clínica y metabolismo. Tercera edición. Copyright 2017 de los autores, SEEN y Grupo Aula Médica.\nTodos los derechos reservados. Páginas 143-153.\n\n1. Introducción y epidemiología\n2. Cirugía bariátrica: Conceptos generales\n3. Cirugía bariátrica: Evaluación preoperatoria y selección de los pacientes\n4. Cirugía bariátrica: Seguimiento postoperatorio\n5. Complicaciones de la cirugía bariátrica\n6. Gestación tras cirugía bariátrica\n7. Resumen y conclusiones\n8. Bibliografía\n\n### 1. Introducción y epidemiología\n\nLa obesidad es una de las enfermedades metabólicas más prevalentes, y se asocia a numerosas complicaciones médicas, psicosociales y a un evidente deterioro en la calidad de vida¹. La obesidad condiciona un aumento de la mortalidad global y da lugar a numerosas enfermedades, como son la diabetes mellitus (DM) tipo 2, el síndrome de apnea obstructiva del sueño, enfermedades articulares, digestivas, endocrinológicas, neoplasias etc.².\n\nLa obesidad es una enfermedad altamente prevalente. Los países con prevalencia más elevada de obesidad, superior al 30%, son EE UU (aproximadamente el 34%), Méjico y Arabia Saudí. En Europa, las tasas más elevadas corresponden a Reino Unido, Alemania, Bulgaria y España.\n\nEn España, la prevalencia de obesidad ha aumentado en los últimos años, especialmente las formas más graves (IMC > 40 kg/m²). Los estudios más recientes (ENRICA³, Di@bet.es⁴ y ENPE⁵) muestran una prevalencia de obesidad entre el 21,6-28,2 y de sobrepeso entre 39,3-51. La mayoría de estos estudios han encontrado un incremento de la prevalencia de la obesidad con la edad, con valor máximo en torno a los 60 años. Es también mayor en el subgrupo poblacional con menor nivel de instrucción\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>IRENE BRETÓN<|>PERSON<|>Irene Bretón is one of the authors associated with the clinical nutrition and dietetics unit at Hospital General Universitario Gregorio Marañón in Madrid.)\n##\n(\"entity\"<|>CYNTHIA GONZÁLEZ-ANTIGÜEDAD<|>PERSON<|>Cynthia González-Antigüedad is one of the authors associated with the clinical nutrition and dietetics unit at Hospital General Universitario Gregorio Marañón in Madrid.)\n##\n(\"entity\"<|>MARTA MOTILLA<|>PERSON<|>Marta Motilla is one of the authors associated with the clinical nutrition and dietetics unit at Hospital General Universitario Gregorio Marañón in Madrid.)\n##\n(\"entity\"<|>ANA ZUGASTI<|>PERSON<|>Ana Zugasti is one of the authors associated with the clinical nutrition and dietetics unit at Hospital General Universitario Gregorio Marañón in Madrid.)\n##\n(\"entity\"<|>PILAR GARCÍA-PERIS<|>PERSON<|>Pilar García-Peris is one of the authors associated with the clinical nutrition and dietetics unit at Hospital General Universitario Gregorio Marañón in Madrid.)\n##\n(\"entity\"<|>HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN<|>ORGANIZATION<|>Hospital General Universitario Gregorio Marañón is a hospital in Madrid that specializes in endocrinology and nutrition.)\n##\n(\"entity\"<|>MADRID<|>GEO<|>Madrid is the capital city of Spain where the Hospital General Universitario Gregorio Marañón is located.)\n##\n(\"entity\"<|>OBESITY<|>EVENT<|>Obesity is a prevalent metabolic disease associated with numerous medical and psychosocial complications, leading to a decline in quality of life.)\n##\n(\"entity\"<|>DIABETES MELLITUS TYPE 2<|>EVENT<|>Diabetes Mellitus Type 2 is a disease associated with obesity, characterized by high blood sugar levels due to insulin resistance.)\n##\n(\"entity\"<|>SLEEP APNEA SYNDROME<|>EVENT<|>Sleep Apnea Syndrome is a condition that can be exacerbated by obesity, leading to interrupted breathing during sleep.)\n##\n(\"entity\"<|>UNIT OF CLINICAL NUTRITION AND DIETETICS<|>ORGANIZATION<|>The Unit of Clinical Nutrition and Dietetics at Hospital General Universitario Gregorio Marañón focuses on the treatment and management of obesity and related conditions.)\n##\n(\"relationship\"<|>IRENE BRETÓN<|>HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN<|>Irene Bretón is affiliated with the Hospital General Universitario Gregorio Marañón as an author in the field of clinical nutrition and dietetics.<|>8)\n##\n(\"relationship\"<|>CYNTHIA GONZÁLEZ-ANTIGÜEDAD<|>HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN<|>Cynthia González-Antigüedad is affiliated with the Hospital General Universitario Gregorio Marañón as an author in the field of clinical nutrition and dietetics.<|>8)\n##\n(\"relationship\"<|>MARTA MOTILLA<|>HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN<|>Marta Motilla is affiliated with the Hospital General Universitario Gregorio Marañón as an author in the field of clinical nutrition and dietetics.<|>8)\n##\n(\"relationship\"<|>ANA ZUGASTI<|>HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN<|>Ana Zugasti is affiliated with the Hospital General Universitario Gregorio Marañón as an author in the field of clinical nutrition and dietetics.<|>8)\n##\n(\"relationship\"<|>PILAR GARCÍA-PERIS<|>HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN<|>Pilar García-Peris is affiliated with the Hospital General Universitario Gregorio Marañón as an author in the field of clinical nutrition and dietetics.<|>8)\n##\n(\"relationship\"<|>OBESITY<|>DIABETES MELLITUS TYPE 2<|>Obesity is a significant risk factor for the development of Diabetes Mellitus Type 2.<|>9)\n##\n(\"relationship\"<|>OBESITY<|>SLEEP APNEA SYNDROME<|>Obesity is associated with an increased risk of developing Sleep Apnea Syndrome.<|>9)\n##\n(\"relationship\"<|>UNIT OF CLINICAL NUTRITION AND DIETETICS<|>HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN<|>The Unit of Clinical Nutrition and Dietetics operates within the Hospital General Universitario Gregorio Marañón, focusing on obesity treatment.<|>8)\n<|COMPLETE|>"}]}